Journal club: orforglipron phase 2 and the non-peptide question Writing it up because I had to work it out twice and would rather nobody else did.
Orforglipron phase 2, and specifically the version of it that the documentation does not cover. The maintained page handles the general case well and stops exactly where my question starts.
Setting out the gap in case it is a gap in the page rather than a gap in what is known.
TRIUMPH (ongoing): Retatrutide phase 3. No results yet. Nothing should be attributed to it because it has not finished. When it does, this discussion will return to it.
Nothing above should be read as advice about what anyone else should do.
I had written a reply contradicting the opening post and deleted it. Here is what survived.
The version of orforglipron phase 2 that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was.
Confirming post #5 from a second method, which matters more than confirming it from a second person.
The most common failure mode is spending fifty minutes on the effect size and ten on the population. Reversing that ratio would improve most sessions.
I have been on both sides of the orforglipron phase 2 argument in this category within eighteen months, which should tell you how strong the evidence for either side is.
Bringing the previous paper on the same question makes the session much better and doubles the preparation. Worth doing every third session rather than every one.
That much is documented. The rest is how I have interpreted it.
Critical appraisal template: (1) What did the trial set out to estimate? (2) Could the design answer that question? (3) Was the population sufficiently similar to your population to apply the results? (4) What was the absolute effect, not just the relative one? (5) What are the two strongest criticisms available?
The strength of my opinion here exceeds the strength of my evidence.
This follows post #10 rather than contradicting it.
The baseline characteristics table is the single most useful page for the questions that get asked here, because it tells you who the result applies to.
Coming back to post #12, because the follow-up matters more than the original answer.
A methods point on orforglipron phase 2 rather than a substantive one: if the comparison is not like for like, the difference you are measuring is the difference in method.
Two people in this thread mean different things by orforglipron phase 2 and are disagreeing about the definition while believing they are disagreeing about the facts. Worth pausing to define it.
Sessions on negative or null results are consistently the most instructive and the hardest to get anyone to attend.
I have said this before in a thread nobody could find, so it is worth repeating.
I read post #16 twice before replying, because I had assumed the opposite.
Reading order that works for these sessions: registry entry, methods, baseline table, primary result, then abstract last. Reading the abstract first anchors everything that follows.
Post #16 put the caveat in the right place and I want to underline it.
Adding a reference point for orforglipron phase 2. Mine is a single case, collected without controls, and I am posting the method alongside it so it can be discounted appropriately.
Where the group cannot agree, record the disagreement rather than resolving it by seniority. The recorded disagreement is more honest and more useful later.
I would call that likely rather than established.
Taking post #21 at face value and following it one step further.
I think the orforglipron phase 2 question is answerable and has not been answered, which is a more optimistic position than most of this thread.
Helpful, and short, which on this subject is harder than long.
I would rather this thread reach "we do not know" about orforglipron phase 2 than reach a confident answer that nobody can support when asked.
The most useful thing anyone has posted about orforglipron phase 2 in this category was a table of what had been measured and by whom. That is what I would want again.
Post #25 is right about the mechanism and I think understates the practical bit.
On orforglipron phase 2, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the range is the interesting bit.
If you can post the two or three numbers you are working from, several people here will check the arithmetic rather than argue about the conclusion.
Orforglipron phase 2 sits at the boundary between what this community can usefully discuss and what it cannot, and I think it falls on the discussable side, narrowly.
Agreed on all of that, and I have nothing to add to it.